Payment overview · 2025
General Payments
$1,334.94
89 reported records · 22 companies
Healthcare provider profile · identity verified
James M. Clements, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GLASGOW, KY · NPI 1417367376
Verified facts
What the public records show
CMS Open Payments records show James M. Clements, M.D. received $1,334.94 in general payments during 2025 across 89 reported records.
ABBVIE INC. accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 323 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $201.26 | 15.1% | 20 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $192.21 | 14.4% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $157.67 | 11.8% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $103.07 | 7.7% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.59 | 5.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.55 | 5.2% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $69.17 | 5.2% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $59.36 | 4.5% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $51.25 | 3.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.70 | 3.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.13 | 3.2% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $34.55 | 2.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.99 | 2.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.84 | 2.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.61 | 2.2% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $25.65 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.26 | 1.7% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.61 | 1.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.80 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.28 | 1.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.30 | 1.1% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $15.09 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,334.94 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $165.32 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $157.67 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $127.77 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $114.24 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $103.07 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $87.02 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $87.02 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $75.59 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $69.17 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $59.36 | 3 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $51.25 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.70 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.13 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.66 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.66 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.55 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $34.55 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.84 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.61 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.89 | 2 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.26 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $12.03 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $12.03 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $12.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 323 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 277 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 115 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 189 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 104 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
277 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
104 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
277 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
115 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
189 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
323 | 50 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1081 | 263 |
| Montelukast Sodium | Montelukast Sodium | 779 | 221 |
| Levothyroxine Sodium | Levothyroxine Sodium | 682 | 159 |
| Pantoprazole Sodium | Pantoprazole Sodium | 627 | 166 |
| Duloxetine Hcl | Duloxetine Hcl | 605 | 135 |
| Lisinopril | Lisinopril | 557 | 126 |
| Losartan Potassium | Losartan Potassium | 520 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 499 | 132 |
| Gabapentin | Gabapentin | 394 | 56 |
| Furosemide | Furosemide | 384 | 100 |
| Omeprazole | Omeprazole | 371 | 98 |
| Metoprolol Tartrate | Metoprolol Tartrate | 348 | 84 |
| Pioglitazone Hcl | Pioglitazone Hcl | 338 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 335 | 80 |
| Eliquis | Apixaban | 323 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 318 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 317 | 76 |
| Metformin Hcl | Metformin Hcl | 296 | 66 |
| Fluticasone Propionate | Fluticasone Propionate | 294 | 102 |
| Clopidogrel | Clopidogrel Bisulfate | 284 | 72 |
| Metformin Hcl Er | Metformin Hcl | 284 | 65 |
| Trazodone Hcl | Trazodone Hcl | 283 | 70 |
| Jardiance | Empagliflozin | 277 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 272 | 110 |
| Potassium Chloride | Potassium Chloride | 269 | 67 |
| Sertraline Hcl | Sertraline Hcl | 260 | 61 |
| Farxiga | Dapagliflozin Propanediol | 238 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 230 | 79 |
| Famotidine | Famotidine | 214 | 57 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 198 | 53 |
| Buspirone Hcl | Buspirone Hcl | 191 | 49 |
| Ozempic | Semaglutide | 189 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 57 |
| Allopurinol | Allopurinol | 166 | 40 |
| Amitriptyline Hcl | Amitriptyline Hcl | 164 | 48 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 163 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 153 | 44 |
| Methocarbamol | Methocarbamol | 150 | 53 |
| Meloxicam | Meloxicam | 148 | 47 |
| Clonidine Hcl | Clonidine Hcl | 146 | 56 |
| Aripiprazole | Aripiprazole | 138 | 36 |
| Donepezil Hcl | Donepezil Hcl | 136 | 19 |
| Januvia | Sitagliptin Phosphate | 134 | 28 |
| Tramadol Hcl | Tramadol Hcl | 134 | 31 |
| Simvastatin | Simvastatin | 128 | 34 |
| Ondansetron Odt | Ondansetron | 125 | 50 |
| Fluconazole | Fluconazole | 123 | 55 |
| Carvedilol | Carvedilol | 120 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 118 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 116 | 29 |
| Mounjaro | Tirzepatide | 115 | 18 |
| Warfarin Sodium | Warfarin Sodium | 115 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 114 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 106 | 29 |
| Lorazepam | Lorazepam | 106 | 13 |
| Finasteride | Finasteride | 105 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 105 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 104 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 104 | 26 |
| Xarelto | Rivaroxaban | 100 | 18 |
| Ezetimibe | Ezetimibe | 96 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | 24 |
| Celecoxib | Celecoxib | 94 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 25 |
| Azelastine Hcl | Azelastine Hcl | 89 | 42 |
| Bupropion Xl | Bupropion Hcl | 85 | 20 |
| Nystatin | Nystatin | 85 | 38 |
| Clonazepam | Clonazepam | 84 | 11 |
| Divalproex Sodium | Divalproex Sodium | 80 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 18 |
| Sucralfate | Sucralfate | 75 | 23 |
| Spironolactone | Spironolactone | 71 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 70 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 19 |
| Nitroglycerin | Nitroglycerin | 65 | 44 |
| Risperidone | Risperidone | 65 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 17 |
| Fenofibrate | Fenofibrate | 63 | 12 |
| Linzess | Linaclotide | 63 | 18 |
| Levetiracetam | Levetiracetam | 61 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 13 |
| Atenolol | Atenolol | 57 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 57 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 21 |
| Mirtazapine | Mirtazapine | 55 | 15 |
| Ranolazine Er | Ranolazine | 55 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 11 |
| Chlorthalidone | Chlorthalidone | 51 | 14 |
| Synthroid | Levothyroxine Sodium | 51 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 35 |
| Doxepin Hcl | Doxepin Hcl | 48 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | 11 |
| Entresto | Sacubitril/Valsartan | 46 | suppressed |
| Glimepiride | Glimepiride | 46 | 14 |
| Mupirocin | Mupirocin | 45 | 35 |
| Benazepril Hcl | Benazepril Hcl | 44 | suppressed |
| Topiramate | Topiramate | 44 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 42 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 14 |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Amoxicillin | Amoxicillin | 41 | 35 |
| Digoxin | Digoxin | 41 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | 12 |
| Pregabalin | Pregabalin | 39 | 12 |
| Bumetanide | Bumetanide | 38 | 13 |
| Naproxen | Naproxen | 38 | 16 |
| Olanzapine | Olanzapine | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 31 |
| Prednisone | Prednisone | 36 | 16 |
| Meclizine Hcl | Meclizine Hcl | 35 | 14 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 27 |
| Ketoconazole | Ketoconazole | 32 | 11 |
| Lactulose | Lactulose | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | 12 |
| Ibuprofen | Ibuprofen | 31 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 20 |
| Valacyclovir | Valacyclovir Hcl | 29 | 16 |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | 11 |
| Ramipril | Ramipril | 28 | suppressed |
| Gemtesa | Vibegron | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 26 |
| Diazepam | Diazepam | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 25 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 25 | 12 |
| Kerendia | Finerenone | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Permethrin | Permethrin | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | 11 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Indapamide | Indapamide | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 15 |
| Valsartan | Valsartan | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Cimetidine | Cimetidine | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,334.94 · 89 records | ABBVIE INC. | ABRYSVO, AREXVY, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FANAPT, Heplisav-B, JARDIANCE, Kerendia, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, Natroba, OTEZLA, Omnipod, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, Spinosad, TRELEGY ELLIPTA, TZIELD, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZURZUVAE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error